Filing Flows › Health Care › Co-Diagnostics (CODX)
Co-Diagnostics (CODX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Co-Diagnostics (CODX) Q2 2026 earnings results →
Q2 2026 Revenue up 2% year over year to $166K
Co-Diagnostics made $166K in Q2 2026 (+2% Y/Y). Operating margin n/m, net loss $6.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $166K in Q2 2026, up 2% year over year and up 14% from the previous quarter.
Gross margin was 72.7%, down 7.6 points from Q2 2025. Operating costs exceeded revenue by $6.2M, an operating margin of -3732.5%. Operating expenses fell 23% while revenue rose 2%. The quarter ended with a net loss of $6.3M, narrower than the previous quarter's $9.1M loss.
Operating cash flow was −$7.2M. Non-cash charges added back $202K of depreciation and amortization and $214K of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$7.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $166K | +2% | n/m | −$6.3M | −$7.2M |
| Q1 2026 | 10-Q | May 14, 2026 | $146K | +190% | n/m | −$9.1M | −$7.8M |
| Q4 2025 | 10-K | Mar 31, 2026 | $264K | +77% | n/m | −$25.7M | −$6.2M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $145K | -77% | n/m | −$5.9M | −$5.9M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $163K | -94% | n/m | −$7.7M | −$8.3M |
| Q1 2025 | 10-Q | May 8, 2025 | $50K | -89% | n/m | −$7.5M | −$8.7M |
| Q4 2024 | 10-K | Mar 27, 2025 | $149K | -96% | n/m | −$11.0M | −$8.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Co-Diagnostics
Co-Diagnostics, Inc., a Utah corporation (the “Company” or “CODX”), develops, manufactures and sells reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. Our diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. CODX’s technical advance involves a novel, proprietary approach to polymerase chain reaction (“PCR”) test design of primer and probe structure (“Co-Primers®”) that dramatically reduces one of the key vexing issues of PCR amplification: the exponential growth of primer-dimer amplification (false positives) which adversely interferes with identification of the target DNA/RNA.
In its own words, from its 10-K, filed Mar 31, 2026.
Co-Diagnostics against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +2% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CODX Co-Diagnostics | Q2 2026 | $166K | +2% | n/m |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Co-Diagnostics 10-Q on SEC EDGAR · CIK 1692415 · Surgical & Medical Instruments & Apparatus
13F: who owns CODX and who is buying
More on CODX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results